Search for: "CELGENE" Results 41 - 60 of 181
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 Jun 2012, 11:02 pm by Mark Summerfield
As we shall explain, the Celgene claims can be shown to be unpatentable based upon some very simple and long-standing principles. [read post]
1 Oct 2008, 3:58 pm
-based Celgene, said it was likely the label for Revlimid would be updated to include reports of the skin reactions. [read post]
17 Aug 2015, 1:46 pm by Gene Quinn
According to Celgene, the Kyle Bass strategy of shorting a stock and filing an inter partes review challenge is an abuse of the process and not what post grant procedures were designed to accomplish. [read post]
12 Oct 2015, 12:46 pm by Gene Quinn
The first bit of good news for Bass came with respect to his IPR petition against Celgene Corporation. [read post]
26 Jan 2012, 8:04 am by By ANDREW POLLACK
Amgen and Celgene are separately acquiring two smaller companies that are harnessing novel technologies to develop drug treatments for leukemias and lymphomas. [read post]
25 Jan 2012, 10:01 pm by Mark Summerfield
  (See Celgene Denied Term Extension on REVLIMID Patent.) [read post]
7 Aug 2019, 2:15 pm by Matthew Rizzolo
But early last week, the Federal Circuit for the first time addressed the applicability of the Takings Clause of the Fifth Amendment to IPRs, holding in Celgene Corp. v. [read post]
2 Aug 2019, 9:43 am by IPWatchdog
This week in Other Barks & Bites: The Federal Circuit issues several precedential decisions, including one reviving the patent claims in VirnetX and another determining that America Invents Act (AIA) validity trials don’t violate the Fifth Amendment’s Takings Clause in Celgene. [read post]
13 Jan 2009, 2:25 pm
  [footnotes omitted] The letter goes on to discuss in some detail several of the SJS, TEN, and EM case reports that Celgene knows about thus far. [read post]
9 Feb 2019, 9:50 pm by Patent Docs
LexisNexis will be offering a webinar on "The Next Billion-Dollar Acquisition in Pharma -- A Forward-Looking Patent Analysis on Bristol-Myers Squibb Acquiring Celgene" on February 11, 2019 at 2:00 pm (ET). [read post]
19 May 2012, 10:25 am
The plaintiff, David Schmidt, alleged retaliation after he blew the whistle against his employer, Celgene Corporation, and CVS/Caremark Corporation, one of Celgene’s distributors. [read post]
20 Sep 2019, 10:16 am by Alaric Dearment - MedCity News
Nine senators sent a letter to FTC Chairman Joseph Simons urging greater scrutiny over like the one between BMS and Celgene, expressing concern over antitrust issues, innovation and drug pricing. [read post]
1 Jul 2010, 9:01 pm by Claire Zillman
Richter represented client Abraxis BioScience on the company's sale to Celgene, negotiating a way for Abraxis's shareholders to benefit from any upside performance beyond the purchase price. [read post]
10 Apr 2017, 5:00 am by John Jascob
The staff said it was unable to concur with Celgene’s view that the proposal could be omitted on any of the three bases. [read post]
27 Jul 2017, 10:37 am by Fraud Fighters
” The allegations against Celgene were brought to court by healthcare whistleblower Beverly Brown, who had been employed as a sales manager by Celgene. [read post]
27 Jul 2017, 10:37 am by Fraud Fighters
” The allegations against Celgene were brought to court by healthcare whistleblower Beverly Brown, who had been employed as a sales manager by Celgene. [read post]
2 May 2018, 2:15 pm by Lawrence B. Ebert
Celgene is selling part of its share in CRISPR Therapeutics.From FiercePharma:Bill Lundberg, M.D., has stepped down as CSO of CRISPR Therapeutics. [read post]
27 Aug 2009, 3:22 pm
Jacobson has now brought a lawsuit against the Celgene Corporation (Jacobson v. [read post]
12 Oct 2015, 12:46 pm by Gene Quinn
The first bit of good news for Bass came with respect to his IPR petition against Celgene Corporation. [read post]